--- title: "VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead" type: "News" locale: "en" url: "https://longbridge.com/en/news/305922449.md" description: "VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing.Original document: Viking Therapeutics, Inc. [VKTX] Slides Release — Nov. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source." datetime: "2026-11-18T06:18:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/305922449.md) - [en](https://longbridge.com/en/news/305922449.md) - [zh-HK](https://longbridge.com/zh-HK/news/305922449.md) generator: "portal-rs" --- # VKTX: VK2735 showed durable weight loss on less-frequent dosing; Phase 3 readouts lie ahead VK2735 maintenance data showed substantial weight loss retained with every-other-week or monthly dosing, while Phase 3 readouts are expected in 2H27 for injectable and 2028 for oral treatment. VK3019 and other metabolic programs are advancing. Original document: Viking Therapeutics, Inc. \[VKTX\] Slides Release — Nov. 18 2026 **Disclaimer** This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source. ### Related Stocks - [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md) ## Related News & Research - [Viking Therapeutics (VKTX) Could Be 77% Undervalued As VK2735 Obesity Data Draws Focus](https://longbridge.com/en/news/305696719.md) - [Viking Therapeutics' VK2735 improves BMI category in 74% of patients in 13-week Phase 2 trial](https://longbridge.com/en/news/305578038.md) - [Viking Therapeutics (VKTX) Stock Trades At A Premium To Book Value](https://longbridge.com/en/news/306273528.md) - [Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026 | VKTX Stock News](https://longbridge.com/en/news/305578185.md) - [Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028](https://longbridge.com/en/news/305443895.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**